Abstract:Hypoxia is a common phenomenon among most solid tumors that significantly influences tumor response toward chemo- and radiotherapy. Understanding the distribution and extent of tumor hypoxia in patients will be very important to provide personalized therapies in the clinic. Without sufficient vessels, however, traditional contrast agents for clinical imaging techniques will have difficulty in accumulating in the hypoxic region of solid tumors, thus challenging the detection of hypoxia in vivo. To overcome this problem, herein we develop a novel hypoxia imaging probe, consisting of a hypoxia-triggered self-assembling ultrasmall iron oxide (UIO) nanoparticle and assembly-responding fluorescence dyes (NBD), to provide dual-mode imaging in vivo. In this strategy, we have employed nitroimidazole derivatives as the hypoxia-sensitive moiety to construct intermolecular cross-linking of UIO nanoparticles under hypoxia, which irreversibly form larger nanoparticle assemblies. The hypoxia-triggered performance of UIO self-assembly not only amplifies its T2-weighted MRI signal but also promotes the fluorescence intensity of NBD through its emerging hydrophobic environment incorporated into self-assemblies. In vivo results further confirm that our hypoxic imaging probe can display a prompt MRI signal for the tumor interior region, and its signal enhancement performs a long-term effective feature and gradually reaches 3.69 times amplification. Simultaneously, this probe also exhibits obvious green fluorescence in the hypoxic region of tumor sections. Accordingly, we also have developed a MRI difference value method to visualize the 3D distribution and describe the extent of the hypoxic tumor region within the whole bodies of mice. Due to its notable efficiency of penetration and accumulation inside a hypoxic tumor, our hypoxia imaging probe could also be considered as a potential candidate as a versatile platform for hypoxia-targeted drug delivery, and meanwhile its hypoxia-related therapeutic efficacy can be monitored.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/jacs.0c10245?goto=supporting-info">https://pubs.acs.org/doi/10.1021/jacs.0c10245</a>.Details of the synthesis, TEM images, in vivo and in vitro biocompatibility (<a class="ext-link" href="/doi/suppl/10.1021/jacs.0c10245/suppl_file/ja0c10245_si_001.pdf">PDF</a>)Three-dimensional (3D) distribution of hypoxic areas within the whole body of 4T1 in situ tumor-bearing mice calculated by the MRI difference value method, where the color moves from blue to red to indicate the hypoxic degree enhancement (<a class="ext-link" href="/doi/suppl/10.1021/jacs.0c10245/suppl_file/ja0c10245_si_002.mp4">MP4</a>)This article has not yet been cited by other publications.

Enhancement of T2* Weighted MRI Imaging Sensitivity of U87MG Glioblastoma Cells Using γ-Ray Irradiated Low Molecular Weight Hyaluronic Acid-Conjugated Iron Nanoparticles

Enhancing MRI imaging through high loading of superparamagnetic nanogels with high sensitivity to the tumor environment

2-Deoxy-d-glucose Modified Supermagnetic Iron Oxide Nanoparticles Enhance the Contrasting Effect on MRI of Human Lung Adenocarcinoma A549 Tumor in Nude Mice

Biocompatibility and proteomic profiling of DMSA-coated iron nanocubes in a human glioblastoma cell line

Citric acid coated ultrasmall superparamagnetic iron oxide nanoparticles conjugated with lactoferrin for targeted negative MR imaging of glioma

Targeted Dual-Contrast T1- and T2-weighted Magnetic Resonance Imaging of Tumors Using Multifunctional Gadolinium-Labeled Superparamagnetic Iron Oxide Nanoparticles

Iron gallic acid biomimetic nanoparticles for targeted magnetic resonance imaging

Fe3O4 Nanoparticles Functionalized with Polymer Ligand for T-1-Weighted MRI in Vitro and in Vivo

Functionalized Ultrasmall Iron Oxide Nanoparticles for T1-Weighted Magnetic Resonance Imaging of Tumor Hypoxia

T2-Weighted Magnetic Resonance Imaging of Hepatic Tumor Guided by SPIO-Loaded Nanostructured Lipid Carriers and Ferritin Reporter Genes

Lactoferrin-conjugated Superparamagnetic Iron Oxide Nanoparticles As a Specific MRI Contrast Agent for Detection of Brain Glioma in Vivo.

Metallic Iron Nanoparticles for MRI Contrast Enhancement and Local Hyperthermia.

MRI Detection and Therapeutic Enhancement of Ferumoxytol Internalization in Glioblastoma Cells

Hsa Coated Mno Nanoparticles With Prominent Mri Contrast For Tumor Imaging

Hyaluronic Acid Stabilized Iodine-Containing Nanoparticles with Au Nanoshell Coating for X-ray CT Imaging and Photothermal Therapy of Tumors.

Holmium (III)-doped multifunctional nanotheranostic agent for ultra-high-field magnetic resonance imaging-guided chemo-photothermal tumor therapy

Hypoxia-Triggered Self-Assembly of Ultrasmall Iron Oxide Nanoparticles to Amplify the Imaging Signal of a Tumor

Hypoxia-Responsive Aggregation of Iron Oxide Nanoparticles for T1-to-T2 Switchable Magnetic Resonance Imaging of Tumors

SPIO-Loaded Nanostructured Lipid Carriers for T2-weighted Magnetic Resonance Imaging of Hepatocarcinoma

Dual-targeting and Excretable Ultrasmall SPIONs for T1-weighted Positive MR Imaging of Intracranial Glioblastoma Cells by Targeting the Lipoprotein Receptor-Related Protein

Magnetic Targeting Combined with Active Targeting of Dual-Ligand Iron Oxide Nanoprobes to Promote the Penetration Depth in Tumors for Effective Magnetic Resonance Imaging and Hyperthermia.